Case report of nivolumab-related pneumonitis. (March 2017)

• Record Type: Journal Article
• Authors: Tada, Kohei; Kurihara, Yasuyuki; Myojo, Tomohiro; Kojima, Fumitsugu; Ishikawa, Yuya; Yoshiyasu, Nobuyuki; Morimoto, Masaya; Ito, Reiko; Koyamada, Ryosuke; Yamashita, Takuya; Bando, Toru; Mori, Shinichiro; Heike, Yuji
• Is Part Of: Immunotherapy. Volume 9:Number 4(2017)
• Page Start: 313
• Page End: 318
• Publication Date: 2017-03
• Subjects: immune-related pneumonitis -- nivolumab -- PD-1 inhibitor; Immunotherapy -- Periodicals; 615.37
• DOI: 10.2217/imt-2016-0129
• Languages: English
• ISSNs: 1750-743X

Abstract

We report a case with suggestive antiprogrammed death-1 inhibitor-related pneumonitis in an endometrial cancer patient. This case presented with fever and cough after three dosages of nivolumab. Computed tomography initially showed centrilobular nodularities in a unilateral lung, which was compatible with aspiration pneumonia. However, diffuse ground-glass opacities (GGO) rapidly developed in the unilateral lung over 4 days despite the use of broad-spectrum antibiotics. Development of GGO was considered to be related to a nivolumab-mediated immune reaction. Corticosteroid was administered and the GGO subsequently disappeared. The present report focuses on the computed tomography diagnostic features of nivolumab-related pneumonitis. The accumulation of knowledge regarding various types of antiprogrammed death-1-related pneumonitis will lead to appropriate treatment for this newly emerging adverse event.